A Multicenter Dose Ranging Clinical Trial of 2',3'-Dideoxycytidine in the Treatment of Patients With AIDS and Advanced ARC.
Status:
Completed
Trial end date:
1990-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety and effectiveness of the drug 2',3'-dideoxycytidine (
zalcitabine; ddC ) in treating patients with AIDS or advanced AIDS related complex ( ARC ).
Recent studies show that a certain group of drugs (dideoxynucleosides) are effective in
treating patients with HIV infection. ddC is a dideoxynucleoside and test tube studies show
that it may be valuable in treating AIDS patients. ddC has been shown to be well tolerated in
certain patients with AIDS.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)